Condition: Leukemia, Lymphoblastic, Acute, Pediatric · Sponsor: Rennes University Hospital
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
This description comes directly from the study's public registry record.
Elie COUSIN, Md · 299284321 · elie.cousin@univ-rennes.fr
marie-laure gervais, phd · 299284321 · marie-laure.gervais@chu-rennes.fr
Always discuss trial participation with your own doctor first.
| CHU Angers | Angers, France | Recruiting |
| CHU Brest | Brest, France | Recruiting |
| CHU Rennes | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649253